Circulating Baseline CXCR3
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
revised:
14
08
2024
received:
09
02
2024
accepted:
19
08
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
aheadofprint
Résumé
The high prevalence of osteoporosis in rheumatoid arthritis (RA) is due to inflammation that stimulates differentiation of osteoclasts, a process involving circulating monocytes and T cell-derived factors. The aim of this study was to evaluate relations between circulating monocytes, T cell subsets, and changes in bone characteristics before and after treatment with biological disease-modifying antirheumatic drugs (bDMARDs) in RA. Thirty patients with untreated early RA who met the American College of Rheumatology/EULAR 2010 criteria were included. Data were collected before and 48 weeks after treatment with methotrexate (MTX) together with one of three bDMARDs (abatacept, tocilizumab, or certolizumab pegol). Disease activity was measured using the Clinical Disease Activity Index, swollen or tender joint counts, C-reactive protein levels, and erythrocyte sedimentation rates. Proportions of monocyte and CD4 HR-pQCT revealed an overall decrease in cortical (P = 0.009) and trabecular (P = 0.034) bone mineral density, although a subset of patients showed no bone loss after 48 weeks of treatment. The overall bone loss was not associated with age, body mass index, sex, intraarticular glucocorticoid injections, or baseline disease activity. Loss of trabecular bone volume fraction correlated with high proportions of circulating CXCR3 MTX together with bDMARDs efficiently reduce disease activity but only prevent bone loss in a subset of patients with RA after 48 weeks of treatment. The correlations of circulating baseline T helper cell and regulatory T cell populations with trabecular bone changes suggest a potential novel role for these cells in systemic bone homeostasis during early RA.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Gustav V's 80 years' foundation
Organisme : Swedish Research Council
ID : 2016-01192
Organisme : Swedish Research Council
ID : 2019-01035
Organisme : Swedish Research Council
ID : 2020-0185
Organisme : IngaBritt and Arne Lundberg Foundation
ID : LU-2018-0008
Organisme : IngaBritt and Arne Lundberg Foundation
ID : LU-2020-0010
Organisme : Nanna Svartz foundation
Organisme : Emil and Wera Cornells foundation
Organisme : The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
ID : ALFGBG-716421
Organisme : The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
ID : ALFGBG-717541
Organisme : The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
ID : ALFGBG-857161
Organisme : The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
ID : ALFGBG-965238
Organisme : Novo Nordisk Foundation Center for Basic Metabolic Research
ID : 19928
Organisme : Association against Rheumatism
Informations de copyright
© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205–2219.
Tourinho TF, Capp E, Brenol JC, et al. Physical activity prevents bone loss in premenopausal women with rheumatoid arthritis: a cohort study. Rheumatol Int 2008;28(10):1001–1007.
Goldring SR. Inflammatory signaling induced bone loss. Bone 2015;80:143–149.
Heinlen L, Humphrey MB. Skeletal complications of rheumatoid arthritis. Osteoporos Int 2017;28(10):2801–2812.
Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid exposure and fracture risk in patients with new‐onset rheumatoid arthritis. Osteoporos Int 2016;27(11):3239–3249.
Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344(8914):23–27.
Haugeberg G, Uhlig T, Falch JA, et al. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety‐four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43(12):2776–2784.
Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(11):1495–1499.
Haugeberg G, Helgetveit KB, Førre Ø, et al. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 2014;15(1):289.
Klose‐Jensen R, Tse JJ, Keller KK, et al. High‐resolution peripheral quantitative computed tomography for bone evaluation in inflammatory rheumatic disease. Front Med (Lausanne) 2020;7:337.
Yue J, Griffith JF, Xu J, et al. Effect of treat‐to‐target strategies on bone erosion progression in early rheumatoid arthritis: an HR‐pQCT study. Semin Arthritis Rheum 2018;48(3):374–383.
Feehan LM, Li LL, McKay HA. Micro‐structural bone changes in early rheumatoid arthritis persist over 1‐year despite use of disease modifying anti‐rheumatic drug therapy. BMC Musculoskelet Disord 2017;18(1):521.
Iwamoto N, Kawakami A. The monocyte‐to‐osteoclast transition in rheumatoid arthritis: recent findings. Front Immunol 2022;13:998554.
Ziegler‐Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol 2013;4:23.
Rossol M, Kraus S, Pierer M, et al. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012;64(3):671–677.
Tsukamoto M, Seta N, Yoshimoto K, et al. CD14brightCD16+ intermediate monocytes are induced by interleukin‐10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther 2017;19(1):28.
Yoon BR, Yoo SJ, Choi Y, et al. Functional phenotype of synovial monocytes modulating inflammatory T‐cell responses in rheumatoid arthritis (RA). PLoS One 2014;9(10):e109775.
Ruiz‐Limon P, Ortega‐Castro R, Barbarroja N, et al; PRECISESADS Clinical Consortium and Flow Cytometry Study Group. Molecular characterization of monocyte subsets reveals specific and distinctive molecular signatures associated with cardiovascular disease in rheumatoid arthritis. Front Immunol 2019;10:1111.
Chiu YG, Shao T, Feng C, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010;12(1):R14.
Yan S, Kotschenreuther K, Deng S, et al. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential. Cell Mol Life Sci 2022;79(10):533.
Yang M, Zhu L. Osteoimmunology: the crosstalk between T cells, B cells, and osteoclasts in rheumatoid arthritis. Int J Mol Sci 2024;25(5):2688.
Khattab SS, El‐Saied AM, Mohammed RA, et al. CD4+ CD25+ CD127low regulatory T cells as indicator of rheumatoid arthritis disease activity. Egypt J Immunol 2016;23(2):87–95.
Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+ CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006;45(10):1210–1217.
Patricia CS, Pedro RN. Physiology and Pathology of Immunology. Nima R, ed. IntechOpen; 2017:chap 8.
Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7(4):R784–R795.
Gerli R, Bistoni O, Russano A, et al. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1‐ and Th2‐type cytokine production at clonal level in different stages of disease. Clin Exp Immunol 2002;129(3):549–555.
Pandya JM, Lundell AC, Hallström M, et al. Circulating T helper and T regulatory subsets in untreated early rheumatoid arthritis and healthy control subjects. J Leukoc Biol 2016;100(4):823–833.
Komatsu N, Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol 2012;3:77.
Yamada A, Takami M, Kawawa T, et al. Interleukin‐4 inhibition of osteoclast differentiation is stronger than that of interleukin‐13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 2007;120(4):573–579.
Silfverswärd CJ, Larsson S, Ohlsson C, et al. Reduced cortical bone mass in mice with inactivation of interleukin‐4 and interleukin‐13. J Orthop Res 2007;25(6):725–731.
Palmqvist P, Lundberg P, Persson E, et al. Inhibition of hormone and cytokine‐stimulated osteoclastogenesis and bone resorption by interleukin‐4 and interleukin‐13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6‐dependent pathway. J Biol Chem 2006;281(5):2414–2429.
Lewis DB, Liggitt HD, Effmann EL, et al. Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci USA 1993;90(24):11618–11622.
Frost A, Jonsson KB, Brändström H, et al. Interleukin (IL)‐13 and IL‐4 inhibit proliferation and stimulate IL‐6 formation in human osteoblasts: evidence for involvement of receptor subunits IL‐13R, IL‐13Rα, and IL‐4Rα. Bone 2001;28(3):268–274.
Aldridge J, Ekwall AH, Mark L, et al. T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3+Th2 phenotype. Arthritis Res Ther 2020;22(1):245.
Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001;98(1):39–45.
Reijm S, Kwekkeboom JC, Blomberg NJ, et al. Autoreactive B cells in rheumatoid arthritis include mainly activated CXCR3+ memory B cells and plasmablasts. JCI Insight 2023;8(20):e172006.
Drevinge C, Scheffler JM, Koro‐Arvidsson C, et al. Intermediate monocytes correlate with CXCR3+ Th17 cells but not with bone characteristics in untreated early rheumatoid arthritis. PLoS One 2021;16(3):e0249205.
Hetland ML, Haavardsholm EA, Rudin A, et al; NORD‐STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:m4328.
Østergaard M, van Vollenhoven RF, Rudin A, et al; NORD‐STAR study group. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48‐week clinical and radiographic results of the investigator‐initiated randomised controlled NORD‐STAR trial. Ann Rheum Dis 2023;82(10):1286–1295.
Glinatsi D, Heiberg MS, Rudin A, et al. Head‐to‐head comparison of aggressive conventional therapy and three biological treatments and comparison of two de‐escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open‐label, blinded‐assessor, phase 4 study. Trials 2017;18(1):161.
Johansson L, Sundh D, Zoulakis M, et al. The prevalence of vertebral fractures is associated with reduced hip bone density and inferior peripheral appendicular volumetric bone density and structure in older women. J Bone Miner Res 2018;33(2):250–260.
MacNeil JA, Boyd SK. Improved reproducibility of high‐resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys 2008;30(6):792–799.
Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93(3):861–868.
Bainbridge KE, Sowers MF, Crutchfield M, et al. Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 2002;156(5):410–417.
Ahlborg HG, Johnell O, Turner CH, et al. Bone loss and bone size after menopause. N Engl J Med 2003;349(4):327–334.
Johannesdottir F, Putman MS, Burnett‐Bowie SM, et al. Age‐related changes in bone density, microarchitecture, and strength in postmenopausal Black and White women: the SWAN Longitudinal HR‐pQCT Study. J Bone Miner Res 2022;37(1):41–51.
Hwang J, Lee EK, Ahn JK, et al. Bone‐density testing interval and transition to osteoporosis in patients with rheumatoid arthritis. Osteoporos Int 2017;28(1):231–237.
Phuan‐Udom R, Lektrakul N, Katchamart W. The association between 10‐year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. Clin Rheumatol 2018;37(10):2603–2610.
Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep 2013;15(10):366.
Wagner CA, Sokolove J, Lahey LJ, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti‐CCP‐negative rheumatoid arthritis: association with cigarette smoking and HLA‐DRB1 ‘shared epitope’ alleles. Ann Rheum Dis 2015;74(3):579–586.
Iwamoto N, Kawakami A. The monocyte‐to‐osteoclast transition in rheumatoid arthritis: recent findings. Front Immunol 2022;13:998554.
Rana AK, Li Y, Dang Q, et al. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 2018;65:348–359.
Carlé C, Degboe Y, Ruyssen‐Witrand A, et al. Characteristics of the (auto)reactive T cells in rheumatoid arthritis according to the Immune Epitope Database. Int J Mol Sci 2023;24(5):4296.
Lee K, Min HK, Koh SH, et al. Prognostic signature of interferon‐γ and interleurkin‐17A in early rheumatoid arthritis. Clin Exp Rheumatol 2022;40(5):999–1005.
Le Goff B, Bouvard B, Lequerre T, et al. Implication of IL‐17 in bone loss and structural damage in inflammatory rheumatic diseases. Mediators Inflamm 2019;2019:8659302.
Kato M. New insights into IFN‐γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med 2020;43(2):72–78.
Scheidt‐Nave C, Bismar H, Leidig‐Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001;86(5):2032–2042.
Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2(5):247–256.